Immunotherapy for HPV negative head and neck squamous cell carcinoma

被引：3

作者：

Jiang, Binyumeng ^{[1
]}

Elkashif, Ahmed ^{[1
]}

Coulter, Jonathan A. ^{[1
]}

Dunne, Nicholas J. ^{[2
]}

Mccarthy, Helen O. ^{[1
]}

机构：

[1] Queens Univ Belfast, Sch Pharm, 97 Lisburn Rd, Belfast BT9 7BL, North Ireland

[2] Dublin City Univ, Sch Mech & Mfg Engn, Dublin, Ireland

来源：

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2024年 / 1879卷 / 05期

关键词：

HNSCC; Vaccines; mRNA; Immunotherapy; T; -cells; Dendritic cells; PHASE-I; DENDRITIC CELLS; T-CELLS; PEPTIDE VACCINE; CANCER VACCINE; TP53; MUTATIONS; COMBINATION; ANTIGEN; PROTEIN; TRIAL;

D O I：

10.1016/j.bbcan.2024.189138

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Head and neck cancer (HNSCC) is the 8th most common cancer in the UK, with incidence increasing due to lifestyle factors such as tobacco and alcohol abuse. HNSCC is an immune-suppressive disease characterised by impaired cytokine secretion and dysregulation of immune infiltrate. As such, immunotherapy is a potential treatment option, with therapeutic cancer vaccination demonstrating the greatest potential. The success of cancer vaccination is dependent on informed antigen selection: an ideal antigen must be either tumour-specific or tumour-associated, as well as highly immunogenic. Stratification of the patient population for antigen expression and validated biomarkers are also vital. This review focuses on the latest developments in immunotherapy, specifically the development of therapeutic vaccines, and highlights successes, potential drawbacks and areas for future development. Immunotherapy approaches considered for HNSCC include monoclonal antibodies (mAb), Oncolytic viral (OV) therapies, Immune Checkpoint Inhibitors (ICIs) and cancer vaccines.

引用

页数：12

共 126 条

[61] Cigarette smoking cessation, duration of smoking abstinence, and head and neck squamous cell carcinoma prognosis [J].

Lee, John J. W. ;

Kunaratnam, Vijay ;

Kim, Christina J. H. ;

Pienkowski, Martha ;

Hueniken, Katrina ;

Sahovaler, Axel ;

Lam, Andrew C. L. ;

Davies, Joel C. ;

Brown, Catherine M. ;

De Almeida, John R. ;

Huang, Shao Hui ;

Waldron, John N. ;

Spreafico, Anna ;

Hung, Rayjean J. ;

Xu, Wei ;

Goldstein, David P. ;

Liu, Geoffrey .

CANCER, 2023, 129 (06) :867-877

[62] Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer [J].

Li, Kai ;

Shi, Houhui ;

Zhang, Benxia ;

Ou, Xuejin ;

Ma, Qizhi ;

Chen, Yue ;

Shu, Pei ;

Li, Dan ;

Wang, Yongsheng .

SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)

[63] G-CSF is a key modulator of MDSC and could be a potential therapeutic target in colitis-associated colorectal cancers [J].

Li, Wenbin ;

Zhang, Xinghua ;

Chen, Yongkang ;

Xie, Yibin ;

Liu, Jiancheng ;

Feng, Qiang ;

Wang, Yi ;

Yuan, Wei ;

Ma, Jie .

PROTEIN & CELL, 2016, 7 (02) :130-140

[64] Cancer vaccines as promising immuno-therapeutics: platforms and current progress [J].

Liu, Jian ;

Fu, Minyang ;

Wang, Manni ;

Wan, Dandan ;

Wei, Yuquan ;

Wei, Xiawei .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)

[65] Synthetic MUC1 breast cancer vaccine containing a Toll-like receptor 7 agonist exerts antitumor effects [J].

Liu, Yu ;

Tang, Li ;

Gao, Ningning ;

Diao, Yuwen ;

Zhong, Jingjing ;

Deng, Yongqiang ;

Wang, Zhulin ;

Jin, Guangyi ;

Wang, Xiaodong .

ONCOLOGY LETTERS, 2020, 20 (03) :2369-2377

[66] Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy [J].

Liu, Zaoqu ;

Zhou, Zhaokai ;

Dang, Qin ;

Xu, Hui ;

Lv, Jinxiang ;

Li, Huanyun ;

Han, Xinwei .

THERANOSTICS, 2022, 12 (14) :6273-6290

[67] Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study [J].

Lynch, Thomas J. ;

Bondarenko, Igor ;

Luft, Alexander ;

Serwatowski, Piotr ;

Barlesi, Fabrice ;

Chacko, Raju ;

Sebastian, Martin ;

Neal, Joel ;

Lu, Haolan ;

Cuillerot, Jean-Marie ;

Reck, Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2046-2054

[68] Peptide-Based Vaccines: Current Progress and Future Challenges [J].

Malonis, Ryan J. ;

Lai, Jonathan R. ;

Vergnolle, Olivia .

CHEMICAL REVIEWS, 2020, 120 (06) :3210-3229

[69] Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer [J].

Matsuzaki, Junko ;

Gnjatic, Sacha ;

Mhawech-Fauceglia, Paulette ;

Beck, Amy ;

Miller, Austin ;

Tsuji, Takemasa ;

Eppolito, Cheryl ;

Qian, Feng ;

Lele, Shashikant ;

Shrikant, Protul ;

Old, Lloyd J. ;

Odunsi, Kunle .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (17) :7875-7880

[70] Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy [J].

McAuliffe, James ;

Chan, Hok Fung ;

Noblecourt, Laurine ;

Ramirez-Valdez, Ramiro Andrei ;

Pereira-Almeida, Vinnycius ;

Zhou, Yaxuan ;

Pollock, Emily ;

Cappuccini, Federica ;

Redchenko, Irina ;

Hill, Adrian V. S. ;

Leung, Carol Sze Ki ;

Van den Eynde, Benoit J. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (09)

← 2 3 4 5 6 7 8 9 10 11 →